UW Spinout, Beat BioTherapeutics, Aims to Make Stem Cells for Damaged Hearts

Xconomy Seattle — 

Stem cell researchers have a lot of big dreams, and one is to someday regenerate damaged hearts. That is still many years away from becoming a commercial reality, if ever, but a few University of Washington scientists have formed a new company that hopes to make cells that can replace pacemakers, and someday rebuild damaged heart tissue that people are left with after heart attacks.

The company, Bellevue, WA-based Beat BioTherapeutics, is the brainchild of Chuck Murry and Michael Laflamme, a pair of UW stem cell researchers, and UW bioengineering professor Buddy Ratner. It has roots in about a decade of research, with $20 million of funding from the National Institutes of Health, Ratner says. No venture capitalists have chipped in to carry this work forward through the early phases of development, although the fledgling company has found another way forward through a partnership with the Bellevue, WA-based Hope Heart Institute, that will provide it with services and support, says CEO Stephen Quinn.

The basic concept of BeatBio, as it’s known for short, is a marriage of stem cell biology and biomedical engineering. Murry and Laflamme’s work has at least partly paved the way for the company to reprogram adult skin cells, to give them vast potential to become other types of cells, like those of the heart. BeatBio specifically wants to direct these cells to become cardiac pacemaker cells, and also cardiomyocytes, the cells that make up heart ventricles. Importantly, scientists have shown the cells can be kept proliferating over time in live animals, Ratner says.

Then comes the engineering part. Normally, when these proliferating cells are injected into the heart, they squirt right out before they can rebuild tissue, Ratner says. BeatBio plans to deliver them via catheter, with a type of bioengineered scaffolding material mounted on the tip. BeatBio hopes that doctors will be able to thread the catheter into the right place in the heart, implant the cells, and use the scaffold as a shield that will keep them in place and alive long enough so they can embed in the heart tissue. Eventually, the new proliferating heart cells will draw support from blood vessels, and thrive on their own, Ratner says.

The market for products that control heart rhythm is worth $10 billion a year, and about 1 million patients worldwide get implanted pacemakers each year, according to Minneapolis-based Medtronic, a leading maker of pacemakers. BeatBio says the market opportunity could be even bigger for an effective new treatment for congestive heart failure. That’s a condition in which the heart enlarges and loses its pumping power, usually after a heart attack causes buildup of scar tissue. About 5.7 million Americans have heart failure, and 670,000 new cases are diagnosed each year, according to the American Heart Association. Plenty of pharmaceutical companies have tried and failed to tap this huge market, but BeatBio insists it sees potential.

“Somebody’s got to be crazy enough to take stem cell therapies to the market,” Quinn says.

So many things could go wrong with this plan, it’s hard to even know where to start. … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

8 responses to “UW Spinout, Beat BioTherapeutics, Aims to Make Stem Cells for Damaged Hearts”

  1. chloe says:

    i read your article on Beat Biotherapeutics. i had to question the NIH funding amount of 20 Million. that is an extreamly large amount of funding considering that grants usually are under 500k. Is the 20million number accurate? can it be varified? i ask because there are many stem cell companies that are underfunded and i have yet to see participation from the NIH at this level before. is this a leading indication of how the Obama administration is going to support stem cell research. if the 20 million figure checks out then i think there is a larger story here. thanks, tony

  2. Here’s Buddy Ratner’s response to the question about the $20 million in NIH support:

    “The $20M number is real. It was a grant at $2 million per year for 10 years in the NIH Bioengineering Research Partnership (BRP) program to Professors Ratner and Murry at the University of Washington (the grant is in its last year).

    Interestingly, the grant started under the G. W. Bush administration. Thus we were limited to approved lines of human embryonic stem cells. Even with this limitation (that we no longer have), we were able to show proof of principle. Of course, the grant was much larger in scope than just stem cells for heart muscle repair — it addressed cell sources, heart mechanics, electrical properties, biomaterials, surgery and other issues.”

  3. Juno says:

    Any updates on how this and other stem cell companies do these days given the current crisis of US economy, consequent reduction of funding from NIH and private sector and yet, more exciting developments in the stem cell field?